Compounding Controversy and FDA Leadership Changes: Key Questions Answered
The U.S. Food and Drug Administration recently made two significant announcements that are reshaping the pharmaceutical landscape. First, the agency proposed removing the active ingredients behind popular obesity and diabetes drugs from a compounding list, a move that directly impacts Novo Nordisk and Eli Lilly. Second, a new acting director has been appointed to lead the Center for Biologics Evaluation and Research (CBER), following the departure of a controversial predecessor. These developments have broad implications for drug availability, patient access, and regulatory oversight. Below, we answer key questions to help you understand what's happening.
What did the FDA propose regarding compounding of obesity and diabetes drugs?
The FDA has proposed removing the active ingredients in two blockbuster drug classes—semaglutide and tirzepatide—from a list of substances that large compounding facilities can use to produce bulk quantities of medicines. Semaglutide is the key component in Novo Nordisk's weight-loss drug Wegovy and diabetes treatment Ozempic, while tirzepatide is found in Eli Lilly's Mounjaro (diabetes) and Zepbound (obesity). The agency determined that there is no clinical need for mass production of these compounded versions, effectively barring large-scale compounders from manufacturing them.
Why did the FDA decide to exclude these ingredients from the compounding list?
The FDA's decision stems from a legal evaluation. Under federal law, large outsourcing facilities can only compound drug ingredients that are not commercially available in sufficient quantity or for which there is a documented shortage. The agency concluded that semaglutide and tirzepatide do not meet these criteria. Over the past few years, compounding pharmacies had increasingly produced weight-loss treatments, sparking controversy about safety and market disruption. The FDA explained that these compounders no longer meet the legal requirements to market their products, making this ruling a significant shift in regulatory enforcement.
How does this decision affect Novo Nordisk and Eli Lilly?
For Novo Nordisk and Eli Lilly, the FDA's proposal is a clear victory. The drugmakers have faced growing competition from compounding pharmacies that offered cheaper, unapproved versions of their blockbuster drugs. By restricting compounded forms of semaglutide and tirzepatide, the FDA helps protect their patents and market share. However, the decision also shifts responsibility for patient access back to the manufacturers, which face ongoing challenges in meeting demand for these highly popular medications. The companies will likely need to ramp up production or develop alternative strategies to ensure supply.
What options do consumers have now for obtaining these drugs?
Consumers seeking semaglutide or tirzepatide will primarily have to rely on branded prescriptions filled at standard pharmacies. Compounding facilities that serve individual patients with specific medical needs—based on a doctor's prescription for a unique formulation—may still operate, but large-scale bulk compounding is effectively prohibited. Patients who previously used compounded versions should consult their healthcare providers to transition to FDA-approved options. Meanwhile, the FDA encourages patients to avoid unapproved compounded drugs, which can lack safety and efficacy guarantees.
Who is the new acting director of CBER, and why was she appointed?
The FDA named Katherine Szarama as the acting director of the Center for Biologics Evaluation and Research (CBER), which oversees vaccines, gene therapies, and the blood supply. She replaces Vinay Prasad, who left the agency after a tumultuous tenure marked by controversial decisions on rare disease drugs and vaccines. FDA Commissioner Marty Makary had announced in March that Prasad would return to the University of California, San Francisco. Szarama joined the FDA late last year as Prasad's deputy, and her appointment is seen as a stabilizing move while the agency searches for a permanent director.
What is Katherine Szarama's background, and what challenges does she face?
Katherine Szarama has a background in regulatory science, having previously served in senior roles at the FDA's Center for Drug Evaluation and Research before moving to CBER as deputy director. Her experience includes oversight of biologic products and vaccine safety. She now faces the challenge of restoring confidence in CBER after Prasad's divisive leadership. Key issues on her plate include managing the review of novel gene therapies and ensuring the reliability of the blood supply. While her appointment is initially acting, government sources have indicated that other candidates—such as ophthalmologist and biopharma executive Houman Hemmati—were considered for the permanent role.
Why did Vinay Prasad leave the FDA, and what does his departure mean?
Vinay Prasad, a former academic with strong opinions on drug pricing and vaccine policy, left the FDA after less than a year as CBER director. His tenure was marked by controversial decisions that drew criticism from both industry and public health advocates. He was known for questioning the effectiveness of some rare disease therapies and raising skepticism about COVID-19 vaccine mandates. His departure, prompted by a return to academia at UCSF, signals a shift in the agency's leadership style. The FDA now has an opportunity to appoint a more consensus-building leader, though Prasad's short tenure also highlights the challenges of leading a complex regulatory body during politically charged times.
How are these two FDA actions connected, and what broader trends do they reflect?
Both actions—the compounding rule change and the CBER leadership shake-up—reflect the FDA's evolving approach to drug oversight during a period of intense public scrutiny. The compounding decision shows the agency prioritizing safety and market integrity, even at the cost of limiting access to popular but unapproved drugs. Meanwhile, the leadership change at CBER underscores the difficulty of balancing innovation with rigorous regulation. Together, these moves suggest the FDA is tightening its grip on drug manufacturing and biologics review, aiming to restore stability after recent controversies. For the pharmaceutical industry, these developments signal a more assertive regulator that is willing to take tough stands.